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Abstract
Vascular endothelial growth factor (VEGF) blockade is an effective therapy for human cancer, yet virtually all
neoplasms resume primary tumor growth or metastasize during therapy. Mechanisms of progression have been
proposed to include genes that control vascular remodeling and are elicited by hypoperfusion, such as the
inducible enzyme cyclooxygenase-2 (COX-2). We have previously shown that COX-2 inhibition by the celecoxib
analog SC236 attenuates perivascular stromal cell recruitment and tumor growth. We therefore examined the effect
of combined SC236 and VEGF blockade, using the metastasizing orthotopic SKNEP1 model of pediatric cancer.
Combined treatment perturbed tumor vessel remodeling and macrophage recruitment, but did not further limit
primary tumor growth as compared to VEGF blockade alone. However, combining SC236 and VEGF inhibition
significantly reduced the incidence of lung metastasis, suggesting a distinct effect on prometastatic mechanisms.
We found that SC236 limited tumor cell viability and migration in vitro, with effects enhanced by hypoxia, but did
not change tumor proliferation or matrix metalloproteinase expression in vivo. Gene set expression analysis (GSEA)
indicated that the addition of SC236 to VEGF inhibition significantly reduced expression of gene sets linked to
macrophage mobilization. Perivascular recruitment of macrophages induced by VEGF blockade was disrupted in
tumors treated with combined VEGF- and COX-2-inhibition. Collectively, these findings suggest that during VEGF
blockade COX-2 may restrict metastasis by limiting both prometastatic behaviors in individual tumor cells and
mobilization of macrophages to the tumor vasculature.
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Background
Agents that inhibit vascular endothelial growth factor
(VEGF) signaling are increasingly incorporated into treat-
ment regimens for metastatic human cancer, yet the over-
all benefit of this treatment strategy has been relatively
modest [1,2]. Both clinical and experimental studies indi-
cate that many or most malignancies will ultimately pro-
gress if VEGF blockade is sustained, and that progression
may involve both progressive primary tumor growth and
enhanced metastasis. The mechanisms for acquired resis-
tance to this treatment approach are thus of great interest,
but are still emerging. We previously found that VEGF
inhibition significantly reduced primary tumor growth and
the incidence of spontaneous lung metastasis in the ortho-
topic renal SKNEP1 tumor model over a six week treat-
ment period, and regressed established metastases in late-
stage tumors [3,4]. Recent findings, however, indicate that
disruption of VEGF signaling and consequent tumor
hypoxia may ultimately promote invasion and metastasis
in several tumor models [5,6], overcoming the initial anti-
metastatic effects of limiting angiogenesis. Prior studies
suggest that hypoxia-regulated and proinflammatory genes
expressed by tumor cells and stroma, such as COX-2, can
promote the establishment of metastatic deposits in the
lung. For example, Massague and coworkers previously
found that COX-2 and other genes involved in vascular
remodeling, identified as components in a “lung metastasis
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gene signature”, functioned collectively to promote metas-
tasis in a breast cancer model [7,8]. More broadly, much
recent data supports a role for systemic inflammation in
the promotion of metastasis in general [9], including disse-
mination to the lung [10]. For example, mice genetically
prone to autoimmune arthritis are significantly more
prone to develop lung metastasis than nonarthritic con-
trols [11]. Recruitment of COX-2-expressing macrophages
can create an inflammatory proangiogenic environment
that strongly promotes tumor growth [12].
Prior work demonstrates that the celecoxib analog
SC236 can reduce spontaneous and experimental metas-
tasis, although it is not clear whether this is due to
effects on individual tumor cells, on the primary tumor
(e.g. angiogenesis), or on the host environment [13].
Thus, it is not known whether the addition of SC236
would limit spontaneous lung metastasis in hypoper-
fused tumors as occurs during VEGF blockade, when
primary tumor angiogenesis is restricted but other pro-
metastatic mechanisms may be active.
In previous studies in the SKNEP1 model, we found
that treatment with SC236 perturbed tumor angiogenesis
and reduced tumor weights [14]. SC236 treatment
resulted in the formation of erratic, segmentally dilated
tumor vessels, marked by a decrease in early pericytes
and a marked reduction in differentiated vascular mural
cells (VMC). These alterations in vessel structure
observed in SC236-treated xenografts differed strikingly
from those previously found in this same model during
administration of blocking anti-VEGF antibody [15]. The
potential importance of remodeling is supported by pre-
vious work indicating that periendothelial mural cells
serve to protect endothelium during VEGF withdrawal
[16], and by experiments showing that targeting VMC
(e.g. by blockade of platelet-derived growth factor B sig-
naling) in combination with VEGF inhibition enhances
anti-angiogenesis [17,18]. It is not known whether SC236
attenuates acquisition or function of perivascular stromal
cells during VEGF inhibition, thus potentially reducing
vessel stability.
In these studies, we used the SKNEP1 model to ask
whether COX-2 inhibition might increase the efficacy of
VEGF blockade, either by attenuating vessel remodeling,
reducing primary tumor blood flow and tumor growth,
or by improving control of metastasis. We asked whether
restriction of metastasis could be mediated by direct
effects of SC236 on SKNEP1 tumor cells, and whether
these were altered in hypoxia, by studying tumor prolif-
eration in vivo during SC236 and anti-VEGF treatment,
and metabolic and invasive properties of tumor cells in
vitro. We asked whether tumor expression of a subset of
a lung metastasis signature containing COX-2 [7], and
more broadly if expression of genes involved in macro-
phage recruitment, changed during SC236 treatment.
Because these mechanisms may collectively contribute to
tumor progression in conditions of reduced perfusion,
understanding the effects of COX-2 inhibitors during
VEGF blockade may hold promise for improving the use-
fulness of this treatment strategy.
Materials and methods
Cell line
The cell line SKNEP-1 (obtained from the American
Type Culture Collection, Manassas, VA) was maintained
in culture in 75-cm2 flasks with McCoy’s 5A medium
(Mediatech, Fisher Scientific, Springfield, NJ). Medium
was supplemented with 10% fetal bovine serum and 1%
penicillin/streptomycin (Life Technologies, Grand Island,
NY). Cells were grown at 37°C in 5% CO2 until conflu-
ent, harvested, counted with trypan blue staining,
washed, and resuspended in sterile PBS (Life Technolo-
gies) at a concentration of 107 per mL.
Animal model
The Institutional Animal Care and Use Committee of
Columbia University approved all experiments. Four- to
6-week-old female NCR nude mice (National Cancer
Institute at Frederick, Frederick, MD) were housed in a
barrier facility and acclimated to 12-hour light/dark
cycles for at least 24 hours before experimental use.
Tumor implantation
Mice (n = 62) were anesthetized with intraperitoneal
ketamine (50 mg/kg) and xylazine (5 mg/kg). The left
flank was prepared in a sterile fashion, and an incision
was made, exposing the left kidney. An inoculum of 106
SKNEP1 tumor cells in 0.1 ml of PBS was injected into
the renal parenchyma using a 25-gauge needle. The flank
musculature was closed with a single 4-0 Polysorb suture
(U.S. Surgical, Norwalk, CT), and the skin incision was
closed with staples.
Administration of SC236 and anti-VEGF antibody
One week after tumor implantation, animals were divided
into four cohorts. Treated mice received either (1) SC236
(N = 17; Pfizer, Groton, CT) added to drinking water at a
concentration of 30 μg/mL and changed thrice per week
as previously described [14]; (2) the humanized monoclo-
nal anti-VEGF antibody bevacizumab (N = 17; BV; Genen-
tech, South San Francisco, CA) injected intraperitoneally
at 10 mg/kg biweekly beginning at week 3; or (3) com-
bined agents (N = 15). Control mice (N = 13) received
standard drinking water and were injected with carrier
vehicle on the same schedule. This concentration of
SC236 is equivalent to ~6 mg/kg/d (anticipated SC236
plasma level 5 μg/ml). Plasma levels of SC-236 were pre-
viously confirmed in our model by high-performance
liquid chromatography (HPLC) [14].
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Harvesting of specimens and determination of metastases
At sacrifice, tumors and contralateral kidneys were
removed, weighed, and then preserved in 4% paraformal-
dehyde for immunohistochemistry. Portions of tumor
were flash frozen in liquid nitrogen and stored at -80°C.
Both lungs were fixed in 10% formalin for histology.
Slides of paraffin-embedded lung tissue were stained by
routine H&E methods and examined by a surgical
pathologist to determine the presence or absence of
metastases, using three levels from each lung.
Immunohistochemistry
Endothelial cell immunofluorescent staining was done
using a rat anti-mouse anti-platelet-endothelial cell adhe-
sion molecule-1 (PECAM-1) monoclonal antibody
(MAP0032, Angioproteomie, Boston, MA). Vascular
mural cells (VMC) were visualized using a rabbit anti-
human a-smooth muscle actin (aSMA) antibody (RB-
9010, Lab Vision/Neomarkers, Fremont, CA). Macro-
phages were visualized using an anti-murine F4/80 anti-
body (Abcam, AB6640) and an anti-arginase antibody
(Santa Cruz Biotech, SC-20150). All microscopy was
done using a Nikon Eclipse E600 apparatus.
Quantification of proliferation
In vivo tumor proliferation (N = 3 for all groups) was
examined by immunofluorescent staining for anti-phos-
pho-histone H3 (Upstate, Inc., Lake Placid, NY), and
quantified by computer-assisted image analysis (23-30
fields per group examined).
MMP-2 and -9 zymography
Tumor extracts (N = 3 for each group) were normalized
for protein content, mixed with nonreducing sample buf-
fer, and electrophoresed in 10% polyacrylamide gels copo-
lymerized with 1 mg/mL of gelatin. After electrophoresis,
gels were washed twice for 15 min in 2.5% Triton X-100,
rinsed with water, and incubated overnight in activation
buffer (50 mM/L Tris-HCl, pH 7.5, 5 mM/L CaCl2) at
37°C. Digested gelatin bands were visualized by staining
with 0.1% Coomassie blue R-250 in 40% methanol/20%
acetic acid. Pooled MMPs were used as a positive control
(US Biological). Bands were optically scanned for
quantification.
MTT Assay
2 × 105 SKNEP cells/well were incubated on a 24-well
plate (BD Labware, Franklin Lakes, NJ) for 24 hours.
Media was then replaced with control media or media
with 25 or 50 uM SC-236 (Pfizer, New York, NY) and
incubated for 24 or 96 hours at 37°C in either normoxia
(21% oxygen) or hypoxia (2.3% oxygen). After the incuba-
tion period, media was aspirated and replaced with
serum-free media and MTT labeling reagent (Roche,
Indianapolis, IN). After 24 hours, 600 uL isopropanol was
added to each well and the resultant solution read in a
Life Science UV spectrophotometer (Beckman, Fullerton,
CA) at wavelengths of 550 and 690 nm. All samples were
plated in triplicate and experiments were repeated 3
times. Assays were repeated with added bevacizumab
(100 ng/ml).
Invasion Assay
SKNEP cells were serum-starved for 24 hours. 5 uM
Cell Tracker Green (Invitrogen) was added to the cells
and incubated for 45 min. Media was then aspirated and
cells incubated in serum-free McCoy’s solution for an
additional 45 min. 8 × 105 cells/well were plated in
24-well, 8 um pore, Matrigel-coated Tumor Invasion
System plates (BD Biosciences) with serum-free media
containing 0 (control), 25, or 50 uM SC-236. The same
media with 15% FBS was added to the lower well, and
the plate incubated for 24 hours in either normoxia or
hypoxia (as above). Invading cells were quantified using
a Cytofluor series 4000 Fluorescence multi-well plate
reader (Applied Biosystems, Foster City, CA) at an exci-
tation wavelength of 485 nm and an emission wave-
length of 530 nm. All samples were plated in triplicate
and experiments were repeated 3 times.
Apoptosis
105 tumor cells per well were plated on a 96-well Microt-
est Tissue Culture Plate (BD Labware). Either media or
media with 25 or 50 uM SC-236 was added, and allowed
to incubate in either normoxia or hypoxia for 20 hours.
Apoptosis was analyzed using the Cell Death Detection
Elisa kit (Roche, Indianapolis, IN). Briefly, media was
aspirated, and cells lysed. After a 30 minute incubation
period, the solution was centrifuged at 1250 rpm for
10 minutes and the supernatant added to a streptavidin-
coated plate. A mixture of anti-histone-biotin and anti-
DNA-peroxidase solution was added to each well and
mixed for 2 hours. Substrate was then added, and color
intensity read using a VersaMax tunable microplate
reader (Molecular Devices, Sunnyvale, CA) at a wave-
length of 405 nm. Camptothecin was used as a positive
control for apoptosis.
Real-time PCR for lung metastasis signature genes
Total RNA was isolated from xenograft tumors (N = 4
each), using an Ambion ToTally RNA Extraction kit
(Ambion, Austin, TX). Real-time PCR was performed
using Taqman probes and an ABI 7300 (Applied Biosys-
tems). Normalization of genes of interest was done uti-
lizing the geNorm method described by Vandesompele
et al [19]. Six human housekeeping genes (ACTB,
HMBS, UBC, GAPD, HPRT, PPIA) were used as refer-
ence controls.
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Microarrays and gene set expression analysis
HG-U133A GeneChips (Affymetrix, Santa Clara, CA)
were used to investigate gene expression in xenografts.
cRNA probes were synthesized as recommended by Affy-
metrix. Briefly, total RNA was isolated in two steps using
ToTALLY RNA Total RNA isolation kit (Ambion,
Austin, TX) followed by RNeasy (Qiagen, Valencia, CA)
purification. Double-stranded cDNA was generated from
5 μg of total RNA using a polydT oligonucleotide that
contained a T7 RNA polymerase initiation site and the
Superscript Choice System kit (Invitrogen, Carlsbad,
CA). Biotinylated cRNA was generated by in vitro tran-
scription using the Bio Array High Yield RNA Transcript
Labeling System (Enzo, Farmingdale, NY). cRNA was
purified using RNeasy and fragmented according to the
Affymetrix protocol, and 15 μg of biotinylated cRNA
hybridized to HGU133A microarrays (Affymetrix). Raw
CEL files were processed using Bioconductor packages in
an R environment http://www.bioconductor.org) [20].
Briefly, quality controls were performed by inspecting
Affymetrix® metrics using the simpleaffy package. Probe
level signals were then background-corrected, normal-
ized, and summarized using the GC-RMA function. Dif-
ferential gene expression was computed using an
Empirical Bayesian model implemented in the Limma
package (Additional File 1 Table S1). To determine
whether the addition of SC236 broadly changed inflam-
mation-related pathways in BV-treated tumors, we used
Gene Set Expression Analysis and GenePattern tools
(GSEA, Broad Institute, Cambridge, MA). The MSigDB
gene set database (5,542 total sets) was queried for gene
sets containing inflammation-related pathways. From
this, we constructed a 67 gene set matrix. GSEA was
used to assess expression of gene sets in this matrix in
BV- and BV+SC236-treated samples (N = 3, 4 respec-
tively). To compute gene enrichment, we permuted by
gene (as recommended for small sample sizes) 5000
times. We then computed odds ratios for the genesets
identified as being significant by GSEA, defined as ratio
of odds for the hits before and after the leading edge. In
particular, for each geneset we computed the following:
oddsRatios =[(Hits/Misses) BeforeTheLeadingEdge]/
[(Hits/Misses) AfterTheLeadingEdge]
We used the odds ratios to additionally filter the
results, as nominal p-value is not informative in this set-
ting, and the NES has a bias towards bigger genesets.
Enzyme-linked immunosorbent assay (ELISA)
ELISA for tumor-derived (human) IL4 was performed
using the Human IL-4 Quantikine HS ELISA Kit HS400
(R&D Systems). All assays were performed in duplicate,
and then repeated twice. Results of repeated assays were
expressed as summary means ± standard error (square
root of interassay variance) [21].
Statistical analysis
Tumor weights were compared by Kruskal-Wallis analysis.
The presence or absence of lung metastases was evaluated
by Fisher’s exact test. Quantitative results of multiply-
repeated MTT, invasion, and ELISA assays were assessed
using Comprehensive Meta Analysis software (Biostat,
Inc., Englewood, NJ). Differences in gene expression by
real-time PCR were compared by Student’s T-test.
Quantification of changes in vasculature
Digital images from immunofluorescence and fluores-
cein-labeled lectin studies were captured from a Nikon
E600 fluorescence microscope with a Spot RT slider
digital camera (Diagnostic Instruments, Sterling Heights,
MI) and stored as TIFF files. Vessel radius was deter-
mined by immunofluorescence for aSMA and analyzed
using software Adobe Photoshop 7.0 (Adobe Systems,
Mountain View, CA) and Image Processing Toolkit
(IPTK 5 IPTK 5, Reindeer Graphics, Raleigh, NC).
Briefly, background fluorescence is subtracted (AutoLe-
velDark), Gaussian filter applied to reduce electronic
and background noise (Gaussian Blur, radius = 1.0
pixel), and grayscale levels linearly expanded (Auto
Levels). A common threshold level is applied that pre-
serves correct vascular morphology (Threshold). The
image is inverted (Invert) and dilated to lessen gaps
(Classic Morphology > Dilate), small particles represent-
ing background removed (Reject Features), and vessel
holes filled in (Fill Holes). The average of the inscribed
radius is determined as a measure of vessel radius. 60
images from SK-NEP1-GFP (3 different tumors) and 49
images from SK-NEP1-Ang1* (3 different tumors) were
analyzed. To assess MVD and vessel length, quantitative
assessment of tumor vessel architecture was performed
by computer-assisted digital image analysis as previously
described [22]. The fraction of fluorescein-labeled lec-
tin-positive pixels per total field was quantified. Specific
changes in vessel architecture are evaluated by quantify-
ing branch points (nodes), end points, and total vessel
length. Images are analyzed after application of a com-
mon threshold, image inversion, morphological erosion,
and skeletonization, again using a combination of
Photoshop and Image Processing Toolkit.
Results and Discussion
The addition of SC236 to VEGF inhibition does not
further restrict tumor size, but does significantly reduce
the incidence of metastasis as compared to anti-VEGF
treatment alone
As compared to controls, SC236 treatment reduced
tumor weight by 39% (P = 0.042, Kruskal-Wallis analysis;
Figure 1A), whereas tumors treated with the anti-VEGF
antibody bevacizumab (BV) were reduced by 76% (P =
0.0002). The addition of SC236 to BV treatment did not
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further decrease primary tumor weight (74% reduction
from controls, P = NS as compared to BV alone). The
incidence of lung metastasis was determined by a surgical
pathologist blinded as to treatment group, examining 3
levels from the entire right lung (Figure 1B). Nearly all of
the control animals had detectable metastases (12/13
mice, 92%). 65% (11/17) of SC236 treated animals had
lung metastases, but this reduction was not statistically
significant. The incidence of metastasis was, however,
significantly reduced in BV-treated mice to 47% (8/17
mice), which was significantly different when compared
to controls (P = 0.011). Strikingly, combining SC236 with
BV treatment caused a further reduction in metastasis
with only 13% (2/15) of mice having lung metastases.
This effect was statistically significant when compared
not only to control tumors (P = 0.0001), but also when
compared to BV treatment alone (P = 0.046). We exam-
ined lung metastases histologically using H&E staining
(Additional File 2 Figure S1). Metastases in combination-
treated mouse lungs appeared smaller than in control or
single-agent treated animals, although the low incidence
of metastasis in this group (2/15) prevented quantitation
of this size reduction. Thus, our data demonstrates that
SC236 when combined with VEGF blockade can mark-
edly reduce distant metastasis, although it does not alter
primary SKNEP1 tumor size, suggesting a differential
effect on this aspect of tumor progression.
The combination of SC236 with VEGF inhibition alters
vascular assembly as compared to either treatment alone
To assess changes in the endothelial component of ves-
sels, we performed immunohistochemistry for platelet
endothelial cell adhesion molecule-1 (PECAM; Figure 2,
left column). Control tumors displayed abundant
PECAM(+) neovasculature, with multiple fine branches
(arrows). Morphologically, both SC236-treated and BV-
treated tumors displayed reduction of branching. In
tumors treated with both BV and SC236, surviving
endothelial vessels were discontinuous, with irregularly
spaced, moderately dilated segments, and near ablation
of branches. Mean vascular density was decreased in all
treated groups as compared to controls (Figure 2B, p <
0.05). To examine differentiated VMC, we immunos-
tained for a-smooth muscle actin (aSMA, Figure 2,
right column). Quantitation of aSMA immunopositive
vasculature demonstrated significant reduction in BV
+SC236 treated tumors as compared to controls (Figure
2C), potentially consistent with a combined effect on
microvessel density and disrupted mural cell coverage of
vessels as previously reported [14]. Thus, the addition of
SC236 to BV treatment may have increased discontinu-
ity in tumor vessel networks, with relative attenuation of
VMC recruitment.
PECAM- and aSMA-immunostaining also suggested
that SC236-treated xenografts were marked by erratically
dilated larger vessels. To quantify this morphologic
change, we measured shifts in distribution of the
inscribed radius of mural cell-covered vasculature (Figure
2D, using a previously described method [22]). SC236-
treated tumor vasculature demonstrated a significant
increase in the vessels with inscribed radius > 10 μm.
Figure 1 The addition of SC236 to bevacizumab significantly
reduces the incidence of metastasis as compared to VEGF
inhibition alone. (A) As compared to controls, SC236 treatment
reduced tumor weight by 39% (P = 0.042), whereas BV-treated
tumors were reduced by 76% (P = 0.0002). The addition of SC236 to
BV treatment did not further decrease primary tumor weight (74%
reduction from controls, P = NS as compared to BV alone). Tumor
weights are expressed as percentage of control tumors, and Kruskal-
Wallis analysis used to determine significance. (B) The incidence of
metastasis was determined by examining 3 levels from the right
lung. 12/13 or 92% of control animals had detectable metastases,
whereas 11/17 (65%) of SC236 treated animals had lung deposits (P
= NS). The incidence of metastasis in BV-treated animals was
significantly reduced as compared to controls (8/17 animals, 47%, P
= 0.011). Combining SC236 with BV treatment further significantly
reduced metastasis (2/15 animals, 13%, P = 0.0001 as compared to
controls and P = 0.046 as compared to BV treatment alone).
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SC236 affects proliferation and invasive properties of
SKNEP1 tumors in vivo and in vitro
We asked whether SC236 caused changes in metastasis-
related tumor cell behaviors under conditions imposed
by VEGF blockade, including proliferation, activation of
matrix metalloproteases (MMP) -2 and -9 and ability to
invade basement membrane. (A) COX-2 is known to
modulate tumor cell proliferation, and we previously
Figure 2 The combination of SC236 with VEGF inhibition alters vascular assembly as compared to either treatment alone. We
performed immunohistochemistry for platelet endothelial cell adhesion molecule-1 to assess changes in endothelial vessels (PECAM; Figure 2,
left column). Control tumors displayed abundant PECAM(+) neovasculature, with multiple fine branches (arrows). Morphologically, both SC236-
treated and BV-treated tumors displayed reduction of branching. In tumors treated with both BV and SC236, surviving endothelial vessels were
discontinuous, with irregularly spaced, moderately dilated segments, and near ablation of branches. Mean vascular density was decreased in all
treated groups as compared to controls (Figure 2B). To examine differentiated VMC, we immunostained for a-smooth muscle actin (aSMA,
Figure 2 right column). Quantitation of aSMA immunopositive vasculature demonstrated significant reduction only in BV+SC236 treated tumors
as compared to controls (Figure 2C), potentially consistent with a combined effect on microvessel density and disrupted mural cell coverage of
vessels as previously reported [14]. PECAM- and aSMA-immunostaining also suggested that SC236-treated xenografts were marked by erratically
dilated larger vessels (arrowheads, Figure 2A). To quantify this morphologic change, we measured shifts in distribution of the inscribed radius of
mural cell-covered vasculature (Figure 2D, using a previously described method [22]). SC236-treated tumor vasculature demonstrated a
significant increase in the vessels with inscribed radius > 10 μm.
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found that SC236 decreased tumor proliferation in vivo.
However, it is not known whether this effect would be
altered in hypoxia, which might enhance sensitivity to
COX-2 or (conversely) stimulate other pathways that
promote proliferation. We quantitated phosphohistone
H3 (pH3), using image analysis of immunofluorescent
staining (N = 3 and 23-30 sections studied, each condi-
tion). SC236 reduced pH3 immunopositive cells in vivo
(Figure 3A), as compared to both control and BV-trea-
ted tumors (33.8 ± 3.2 cells/hpf vs. 53.6 ± 3.6 and 46.4
± 2.8 cells/hpf, respectively; P < 0.005, both). Combined
SC236 and BV treatment also reduced proliferation in
comparison to controls (43.1 ± 2.4 cells/hpf, P < 0.02).
Thus, SC236 restriction of proliferation persisted during
VEGF blockade, but was not significantly altered. (B)
Activation of matrix metalloproteinases has been linked
to metastasis of primary tumors to the lung [23,24], and
can be modulated by VEGF and COX-2 signaling
[25,26]. Using gelatin zymography, we examined MMP-
2 and MMP-9 in tumor samples, and quantified activity
by comparing optical band density in each treatment
group (Figure 3B, N = 3 each). MMP-2 activity was
unchanged in each condition (not shown). MMP-9
activity was significantly reduced in each treatment
Figure 3 SC236 affects proliferation and invasive properties of SKNEP1 tumors in vivo and in vitro. (A) Quantification of phosphohistone
H3 (pH3) (N = 3; 23-30 sections studied, each condition) demonstrated that SC236 reduced proliferation in vivo as compared to both control
and BV-treated tumors (33.8 ± 3.2 cells/hpf vs. 53.6 ± 3.6 and 46.4 ± 2.8 cells/hpf, respectively; P < 0.005, both). Combined SC236+BV treatment
also reduced proliferation versus controls (43.1 ± 2.4 cells/hpf, P < 0.02). Thus, SC236 restriction of proliferation persisted during VEGF blockade,
but was not altered. (B) We assessed MMP-2 and MMP-9 activation, which can promote lung metastasis and interacts with VEGF and COX-2
status, using gelatin zymography [23-26] in each treatment group (N = 3 each). MMP-2 activity was unchanged (not shown). MMP-9 activity was
significantly reduced in each treatment group as compared to controls (versus SC236 group, 35%; in BV, 34%, SC36+BV, 25%; P < 0.03, each).
Thus, combined SC236 and BV did not further reduce MMP9 activity. (C) We used the MTT assay to determine whether hypoxia, SC236
concentration, or duration of exposure would reduce SKNEP1 tumor cell viability. Both hypoxia and increasing concentration suppressed activity
measured by MTT, with effects enhanced by increasing duration (96 h). These results support an increased effect of SC236 in hypoxic conditions,
as may occur during VEGF blockade. (D). We assessed SC236 effect on tumor cell invasion through basement membrane (Matrigel). Invasion was
reduced at 50 μM SC236 by 7% in normoxia and 14% in hypoxia (P < 0.005, each).
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group as compared to controls (versus SC236 group,
35%; in BV, 34%, BV+SC36, 25%; P < 0.03, each). Thus,
combined SC236 and BV did not further reduce MMP9
activity. (C) We used the MTT assay to determine
whether hypoxia, SC236 concentration, or duration of
exposure would reduce viability in SKNEP1 tumor cells.
We have previously reported that 30 μg/mL SC236 in
drinking water results in serum concentrations between
25 and 50 μM/mL [14]; therefore, we tested effects at
these two concentration levels. We found that both
hypoxia and increasing concentration suppressed activity
measured by MTT, with this effect enhanced at
increased duration (96 h). For example, at 24 h signifi-
cant reduction as compared to controls (9.9%, P < 0.001)
was found only at the higher concentration (50 μM) and
in hypoxia, whereas at 96 h significant reduction was
found in normoxia at the 50 μM concentration (8%), and
in hypoxia at both 25 and 50 uM (16% and 44%, respec-
tively; P < 0.001, all). These results support an increased
effect of SC236 in hypoxic conditions, as may occur in
tumor regions during VEGF blockade. We repeated these
studies in the presence of BV, and found no effect. (D)
We assessed the ability of SC236 to restrict tumor cell
invasion through basement membrane (Matrigel), since
intravasation is a key step in metastasis. Invasion was sig-
nificantly reduced only at the 50 μM concentration level,
by 7% in normoxia and 14% in hypoxia (P < 0.005, each),
consistent with a modest restriction by SC236. In sum-
mary, SC236 reduces metastatic behaviors in tumor cells:
proliferation in vivo and viability and migration through
basement membrane in vitro, with the latter two effects
enhanced by hypoxia.
SC236 does not increase apoptosis in SKNEP1 cells in
normoxia or hypoxia
COX-2 signaling can interfere with apoptotic mechan-
isms in some cell types and in some settings. Therefore,
we examined the effect of SC236 on SKNEP1 cell apopto-
sis in vitro. No increase in apoptosis was found at either
concentration of SC236, and no effect of hypoxia was
detected (not shown). Thus, increasing apoptosis may
not contribute to restriction of metastasis in this system.
The addition of SC236 does not alter expression of lung
metastasis signature genes during VEGF blockade
We detected expression of 7 genes (COL6A1, CSF2RA,
CXCR4, KRT81, MATN2, SPARC, TNC) included in the
lung metastasis gene signature described by Minn et
al. [8] in tumor extracts from each group (N = 6, con-
trols, SC236-treated, BV-treated; N = 5, BV+SC236 trea-
ted; Additional File 3 Figure S2). Comparison was
performed by real-time PCR. No significant differences
between BV and SC236+BV treated tumors were found,
suggesting that SC236 did not reduce lung metastasis by
suppressing expression of these genes.
The addition of SC236 alters expression of gene sets
representing macrophage-related inflammatory pathways
in BV-treated tumors
COX-2 activity broadly influences inflammation, which
appear increasingly implicated in tumor development,
progression, and metastasis [9]. It is possible that SC236
improves control of metastasis in BV-treated tumors in
our model by reducing expression of inflammation-
related genes that act in concert. We therefore used
gene set expression analysis (GSEA) and a matrix of 67
gene sets representing pathways linked to macrophage
recruitment selected from the Molecular Signatures
Database (MSigDB, Broad Institute, Cambridge, MA) to
explore this possibility in Affymetrix HGU133A micro-
array datasets from xenografts (N = 3, 4 respectively, for
BV, and BV+SC236 groups). 20 gene sets were signifi-
cantly negatively enriched (repressed) in combination in
SC236+BV treated as compared to BV-treated tumors
(Table 1). No positively enriched gene set had an odds
ratio > 2.0, whereas the top 5 negatively enriched gene
sets were significant both by GSEA normalized enrich-
ment score and had odds ratios > 2. Leading edge analy-
sis of these sets suggested involvement of cytokines,
with interleukin-4 (IL40 the most significantly sup-
pressed gene in the leading edge analysis. IL4 plays a
key role in recruiting and activating tumor-associated
macrophages [27] and can be suppressed by COX-2
inhibition in inflammatory conditions [28]. Therefore,
we examined expression of IL4 protein by ELISA in BV-
treated versus SC236+BV-treated tumors, and found a
60% reduction in combined-treatment tumors (3.1 ± 1.7
pg/ml, BV treated; 1.2 ± 0.3 pg/ml, SC236+BV-treated,
P = 0.056).
Macrophage recruitment is altered by BV and SC236
treatment
These results led us to examine distribution of macro-
phages in treated tumors, using the mouse macrophage
marker F4/80 (Figure 4A). Morphologically, there
appeared to be increased irregularity of the perivascular
F4/80 signal in the combined-treatment group. Quantifi-
cation of F4/80 immunopositivity demonstrated signifi-
cant increase in BV and SC236+BV treated groups as
compared to controls (Figure 4B). To detect shifts in dis-
tribution of polarized macrophages, we performed immu-
nohistochemistry for the M1 marker TNFa (Figure 4C).
TNFa-immunopositive cell distribution appeared similar
to the patterns for F4/80 signal. Immunohistochemistry
for the M2 marker arginase demonstrated immunoposi-
tive cells primarily in necrotic areas of tumors;
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quantification of arginase signal did not change between
treatment groups (data not shown).
Conclusions
While inhibition of VEGF signaling has become an estab-
lished cancer therapy, it has become evident that its over-
all impact is relatively modest, with virtually all patients
developing progressive disease [5,6]. One proposed
mechanism for the limitations of this approach is the
alteration in tumor gene expression induced by hypoper-
fusion. Because it is regulated by hypoxia, a consequence
of treatments that restrict blood supply, COX-2 may par-
ticipate in this compensatory response to VEGF inhibi-
tors. In addition, COX-2 signaling is implicated in
multiple processes that contribute to tumor progression,
including proliferation, survival, angiogenesis, and inva-
sion. In these studies, we asked whether inhibition of
COX-2 by SC236 would enhance the effects of VEGF
blockade in the SKNEP1 model, either by perturbing
compensatory vascular remodeling and primary tumor
perfusion, or by further reducing the incidence of lung
metastasis.
SC236 treatment significantly restricted primary tumor
weight as compared to controls, as did BV. However, the
addition of SC236 to BV treatment did not result in any
further reduction, leading us to ask how this combination
affected tumor vasculature and consequent tumor viability.
As in our prior studies, both agents impaired angiogenesis,
Table 1 The addition of SC236 alters expression of gene sets associated with macrophage recruitment pathways in
BV-treated tumors
POSITIVELY ENRICHED GENE SETS
NAME ES NES NOM p-val FDR
q-val
FWER p-val oddRatios
DNA_METABOLIC_PROCESS 0.3612 1.8297 0.0000 0.0074 0.0134 1.9304
APOPTOSIS_KEGG 0.3195 1.2502 0.1253 0.2551 0.6220 1.9831
SOLUBLE_FRACTION 0.2035 0.9724 0.5341 0.8663 0.9962 1.5214
NEGATIVE_REGULATION_OF_PROGRAMMED_CELL_DEATH 0.1657 0.7811 0.9662 0.8935 1.0000 1.2876
NEGATIVELY ENRICHED GENE SETS
NAME ES NES NOM p-val FDR
q-val
FWER p-val oddRatios
HSA04060_CYTOKINE_CYTOKINE_RECEPTOR_INTERACTION -0.5365 -2.2777 0.0000 0.0000 0.0000 3.5618
CYTOKINE_ACTIVITY -0.5464 -2.1044 0.0000 0.0000 0.0000 3.3868
IMMUNE_RESPONSE -0.4609 -1.9351 0.0000 0.0007 0.0018 2.3685
DEFENSE_RESPONSE -0.4529 -1.9243 0.0000 0.0006 0.0022 2.2449
INFLAMMATORY_RESPONSE_PATHWAY -0.6176 -1.9127 0.0009 0.0006 0.0026 3.4287
REGULATION_OF_MULTICELLULAR_ORGANISMAL_PROCESS -0.4773 -1.9076 0.0000 0.0005 0.0026 2.0887
CYTOKINE_PRODUCTION -0.5188 -1.8253 0.0005 0.0017 0.0108 3.8765
HSA04514_CELL_ADHESION_MOLECULES -0.4568 -1.7974 0.0002 0.0020 0.0144 1.7020
IMMUNE_SYSTEM_PROCESS -0.4064 -1.7650 0.0000 0.0029 0.0230 1.8520
RESPONSE_TO_EXTERNAL_STIMULUS -0.4064 -1.7482 0.0000 0.0032 0.0286 2.0471
INFLAMMATORY_RESPONSE -0.4473 -1.7450 0.0000 0.0031 0.0300 2.1490
POSITIVE_REGULATION_OF_MULTICELLULAR_ORGANISMAL_PROCESS -0.4977 -1.7303 0.0016 0.0035 0.0374 1.5006
RECEPTOR_BINDING -0.3842 -1.6798 0.0000 0.0058 0.0648 1.7643
RESPONSE_TO_WOUNDING -0.4071 -1.6678 0.0000 0.0064 0.0766 2.1108
IMMUNE_EFFECTOR_PROCESS -0.5187 -1.6357 0.0081 0.0082 0.1052 2.5265
LYMPHOCYTE_ACTIVATION -0.4637 -1.6207 0.0046 0.0090 0.1222 1.4574
CELL_ACTIVATION -0.4436 -1.6042 0.0048 0.0102 0.1460 1.9692
LEUKOCYTE_ACTIVATION -0.4516 -1.6008 0.0054 0.0100 0.1516 2.0518
ADAPTIVE_IMMUNE_RESPONSE_GO_0002460 -0.5491 -1.5398 0.0294 0.0181 0.2656 2.1055
ADAPTIVE_IMMUNE_RESPONSE -0.5268 -1.4882 0.0446 0.0280 0.3934 2.3657
To assess the possibility that SC236 improves control of metastasis in the context of VEGF blockade by broadly reducing expression of inflammation-related
genes, we used gene set expression analysis (GSEA) and a matrix of 67 gene sets representing pathways linked to macrophage recruitment selected from the
Molecular Signatures Database (MSigDB, Broad Institute, Cambridge, MA) to explore this possibility in Affymetrix HGU133A microarray datasets from xenografts
(N = 3, 4 respectively, for BV, and BV+SC236 groups). 20 gene sets were significantly negatively enriched (repressed) in combination in SC236+BV treated as
compared to BV-treated tumors; no positively enriched gene set had an odds ratio > 2.0 (Table 1). Among the negatively enriched sets, we selected those with
odds ratios > 3.0 in the top 5 for further analysis. Thus, it is possible that, in the context of VEGF inhibition, SC236 acts in part by limiting the ability of tumors to
promote recruitment of macrophages, key elements in an inflammatory state that facilitates metastasis.
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with reduction in branching and pruning of smaller vessels
[14]. SC236 disrupted vascular assembly, with erratic dila-
tation of large vessels. Tumors treated with combined
agents displayed elements of these two patterns, with pre-
served VMC coverage of surviving vessels but irregular
segmental dilatation and discontinuity. Tumor prolifera-
tion was not further reduced in vivo from treatment with
SC236 alone. Thus, in our model the ability of SC236 to
perturb VMC recruitment did not sufficiently destabilize
vasculature during VEGF inhibition to further limit tumor
growth.
In the SKNEP1 model, inhibition of VEGF reduces the
incidence of lung metastasis, and can cause initial
regression of established metastases in later-stage
tumors [4]. However, SKNEP1 tumors [29] and metas-
tases (our unpublished observation) recur if VEGF
Figure 4 Macrophage recruitment is altered by BV and SC236 treatment. Distribution of macrophages was examined using the mouse
macrophage marker F4/80 (Figure 4A). Morphologically, F4/80 appeared to be increased in BV- and BV+SC236-treated tumors, with somewhat
more irregularity in the latter. Quantified F4/80(+) signal was significantly increased in BV- and SC236+BV-treated groups versus controls (Figure
4B). TNFa-immunopositive cell distribution appeared similar to the patterns for F4/80 signal (Figure 4C). The M2 marker arginase was detected in
cells primarily in necrotic regions, which did not change with treatment (not shown).
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inhibition is prolonged. Thus, our system may serve as
an example of a tumor type in which metastasis is initi-
ally sensitive to VEGF blockade, in contrast to others in
which it may actually be increased [5,6]. The addition of
SC236 to BV treatment did significantly improve control
of metastasis, by reducing incidence. This finding sug-
gests that SC236 may have limited one or more tumor
cell behaviors that specifically contribute to establish-
ment of metastasis, such as the ability to transit tumor
parenchyma, invade vasculature, or survive as implants
in the lung, distinct from effects on primary tumor
growth. Consistent with this concept, proliferation in
primary tumors was not further restricted in BV
+SC236- as compared to SC236-treated xenografts.
However, we found that viability of SKNEP1 cells (as
assessed by MTT) tended to be restricted by SC236 in
vitro in hypoxia, particularly if exposure were prolonged
or at a higher concentration. It is possible that prolifera-
tion is supported in a primary tumor in vivo by secreted
products of adjacent nonhypoxic regions, since BV
+SC236 did not completely devascularize xenografts, or
by host cells that contribute to tumor stroma. Invasion
of tumor cells into basement membrane in vitro was
similarly restricted by 50 μM SC236, with possible
enhancement of this effect by hypoxia. However, while
MMP-9 activity was reduced in both SC236- and BV-
treated tumors, there was no further reduction in activ-
ity in BV+SC236-treated xenografts, suggesting that
decreased invasion may not be mediated by diminished
MMP-9. No effect of SC236 on tumor cell apoptosis
was detected. Taken together, these findings are consis-
tent with an effect on prometastatic behaviors (viability,
invasion of vascular basement membrane) in individual
tumor cells.
Because alteration in COX-2 signaling may affect
tumor cell expression of other genes that specifically pro-
mote lung metastasis, we asked whether SC236 treatment
altered expression of a subset of a previously described
lung metastasis gene signature that includes COX-2 [7,8].
While expression of these genes was detected in our
model system, the addition of SC236 to BV did not
reduce expression as compared to BV-treated tumors.
More broadly, mobilization of macrophages by an inflam-
matory tumor microenvironment can also contribute to
metastasis [9-11]. Given the ability of SC236 to block
COX-2 activity, we asked whether the addition of SC236
to BV treatment limited primary tumor expression of
gene sets implicated in macrophage-related pathways.
Using gene set expression analysis, we found a shift
toward significant suppression of gene sets containing
cytokines that mediate such responses. In particular, we
detected reduced expression of IL4 mRNA and protein.
IL4 plays an established role in activating tumor-asso-
ciated macrophages, and can be regulated by COX-2
activity. Suppression of this cytokine by COX-2 inhibi-
tion in the context of VEGF blockade might therefore
contribute to attenuating a prometastatic tumor micro-
environment. BV treatment quantitatively increased peri-
vascular macrophage recruitment. The addition of SC236
did not limit this increase, or modulate distribution of
cells bearing M1 or M2 markers. Thus, the effect of
SC236 on tumor-associated macrophages in the context
of VEGF blockade does not appear to include quantita-
tive changes in recruitment.
Thus, our data provides evidence that inhibition of
COX-2 may limit metastasis in the setting of VEGF inhi-
bition, distinct from its effect on primary tumor angio-
genesis and growth. Restriction of metastasis may result
from reduced viability or ability to transit basement
membrane in individual tumor cells. In addition, dimin-
ished primary tumor angiogenesis may have limited
tumor cell access to the circulation, limiting hematogen-
ous dissemination. We detected increased perivascular
recruitment of macrophages in BV-treated tumors, and
shifts in gene expression related to macrophage function
between BV- and BV+SC236-treated tumors. However,
we did not detect histologic changes in the distribution
of macrophages when SC236 treatment was added to BV.
Further investigation of functional effects of COX-2
blockade on interaction of tumor cells and stroma may
assist in better understanding of these alterations, and in
optimizing the use of anti-VEGF treatments in cancer
patients at risk for metastatic progression.
Additional material
Additional file 1: Table S1. LimmaAnnotated.xls: Differential gene
expression was computed using an Empirical Bayesian model
implemented in the Limma package. Briefly, we analyzed microarray data
obtained using HG-U133A GeneChips (Affymetrix, Santa Clara, CA) to
investigate gene expression in xenografts. Raw CEL files were processed
using Bioconductor packages in an R environment http://www.
bioconductor.org). Quality controls were performed by inspecting
Affymetrix®® metrics using the simpleaffy package. Probe level signals
were then background-corrected, normalized, and summarized using the
GC-RMA function, and differential gene expression then computed as
above.
Additional file 2: Figure S1. Metastases in combination SC236 and BV-
treated mouse lungs appeared smaller than in control or single-agent
treated animals. The low incidence of metastasis in this group (2/15)
prevented quantitation of this size reduction, although it may reflect
decreased efficiency of metastasis in this group.
Additional file 3: Figure S2. The addition of SC236 does not alter
expression of lung metastasis signature genes during VEGF blockade. We
examined expression of 7 genes (COL6A1, CSF2RA, CXCR4, KRT81,
MATN2, SPARC, TNC) included in the lung metastasis gene signature
described by Minn et al. (8) in tumor extracts from each group (N = 6,
controls, SC236-treated, BV-treated; N = 5, BV+SC236 treated).
Comparison was performed by real-time PCR. No significant differences
between BV and SC236+BV treated tumors were found, suggesting that
SC236 did not reduce lung metastasis by suppressing expression of
these genes.
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